TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.

Trial Details

NCT ID
NCT06206174
Phase
PHASE1 / PHASE2
Sponsor
Shenzhen TargetRx Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • TGRX-814
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • male or female ≥ 18 years of age
  • fully understand the requirements of the study and voluntarily sign a written informed consent form
  • diagnosis of NHL, ALL, AML or MDS
  • Eastern Cooperative Oncology Group (ECOG) physical status score ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →